AI Article Synopsis
- - The study analyzed data from 8601 patients to assess how chemotherapy affects stage IA triple-negative breast cancer.
- - There was a significant increase in chemotherapy use from 2010 to 2019 for patients with T1b and T1c tumor sizes.
- - Receiving chemotherapy was linked to better breast cancer-specific survival, especially for those with T1c tumors, showing a notable survival rate improvement over five years.
Article Abstract
To evaluate the role of chemotherapy in stage IA triple-negative breast cancer, we conducted a retrospective population-based study including 8601 patients. The use of chemotherapy significantly increased from 2010 to 2019 in patients with T1b and T1c tumors (p = 0.001 and p < 0.001, respectively). Receipt of chemotherapy was associated with improved breast cancer-specific survival (BCSS, adjusted hazard ratio = 0.70; p = 0.006), particularly in patients with T1c tumors (5-year BCSS 94.5% vs. 91.2%).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10995121 | PMC |
| http://dx.doi.org/10.1038/s41523-024-00634-6 | DOI Listing |
Publication Analysis
Top Keywords
stage triple-negative
8
triple-negative breast
8
breast cancer
8
prognosis treatment
4
treatment outcomes
4
outcomes patients
4
patients stage
4
cancer evaluate
4
evaluate role
4
role chemotherapy
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!